eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Novartis Consumer Health
Wimblehurst Road, Horsham, West Sussex, RH12 5AB
Telephone: +44 (0)1403 210 211
Fax: +44 (0)1403 323 919
Medical Information Direct Line: +44 (0)1403 323 046
Medical Information e-mail: medicalaffairs.uk@novartis.com
Customer Care direct line: +44 (0)1403 218 111
Medical Information Fax: +44 (0)1403 324 024

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 04/08/2008
SPC Savlon Bites & Stings Pain Relief Gel


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Savlon Bites & Stings Pain Relief Gel


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredients:

Lidocaine Hydrochloride 2.0% w/w

Zinc Sulphate 1.0% w/w

Cetrimide 0.5% w/w

For Excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Gel

Colourless, viscous gel with a characteristic menthol odour


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the symptomatic relief of pain, itching, irritation, and for antiseptic protection. For use in insect bites and stings, and skin reactions such as nettle rash, caused by contact with plants.


Go to top of the page
4.2 Posology and method of administration

Adults and children over 12 years:

Apply a small amount to the affected area with a fingertip.

Repeat if required up to 3-4 times daily.

Children under 12 years:

Not recommended (insufficient data available).

Route of administration:

For cutaneous use


Go to top of the page
4.3 Contraindications

Patients with a known hypersensitivity to any ingredient should not use the product


Go to top of the page
4.4 Special warnings and precautions for use

Contact with the eyes should be avoided.

For external use only.

Not suitable for animal bites.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No known interactions with other drugs.


Go to top of the page
4.6 Pregnancy and lactation

There are no known adverse effects in normal use of this product in pregnancy and lactation.

Exposure to systemically absorbed lidocaine from the product is low. The active ingredients have been in use for many years and no special precautions are considered necessary.


Go to top of the page
4.7 Effects on ability to drive and use machines

There are no known adverse effects on driving and using machinery.

The active ingredients have been in use for many years at much higher levels of exposure and no precautions are considered necessary for use in driving and using machinery.


Go to top of the page
4.8 Undesirable effects

Rarely, skin irritation and sensitisation may occur.


Go to top of the page
4.9 Overdose

Overdosage effects are unlikely as the systemic dose from this topical product is likely to be very low.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Three pharmacological effects are provided:

Lidocaine hydrochloride is a local anaesthetic of the amide type which is widely used for local application to the skin and mucous membranes. It produces surface anaesthesia by diminishing or preventing the conduction of sensory nerve impulses.

Cetrimide is a quaternary ammonium antiseptic. As well as having emulsifying and detergent properties, it has antibacterial activity against gram-positive organisms and to a lesser extent against some gram-negative organisms.

Zinc sulphate has astringent and soothing properties.


Go to top of the page
5.2 Pharmacokinetic properties

The product is intended for local action. Lidocaine hydrochloride is well-absorbed through mucous membranes and more slowly absorbed through intact skin.


Go to top of the page
5.3 Preclinical safety data

No relevant information is available other than that given in other sections of the SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Hydroxyethylmethylcellulose

Polysorbate 20

Nonoxynol 9

Propylene Glycol

Levomenthol

Purified Water


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

36 months.

Shelf life following opening of the tube: 3 months.


Go to top of the page
6.4 Special precautions for storage

Do not store above 30°C


Go to top of the page
6.5 Nature and contents of container

Laminated tube consisting of aluminium foil coated internally and externally with low density polyethylene or high density polyethylene.

Pack size: 3g, 20g


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Novartis Consumer Health UK Ltd

Wimblehurst Road

Horsham

RH12 5AB

West Sussex

Trading Style: Novartis Consumer Health


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00030/0161


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

15 February 2001


Go to top of the page
10. DATE OF REVISION OF THE TEXT

31 October 2006

Legal category: GSL



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/21045/SPC/


Active Ingredients/Generics

 
  cetrimide
  zinc sulphate monohydrate
  lidocaine hydrochloride